Every savings route has a gate, and the gates rarely overlap. Copay cards need commercial insurance. Manufacturer self-pay channels need the absence of coverage. Foundations need a financial threshold. Discount platforms need nothing but are not insurance. Knowing which gate you fail is faster than applying to everything and being declined.
Eligibility is a set of gates, not a ladder
People often work through savings options as if they were rungs, trying the biggest advertised reduction first and stepping down. That wastes time, because these programs are not ranked versions of the same thing. They are separate mechanisms built for separate populations, and the qualifying condition for one is frequently the disqualifying condition for another.
Commercial insurance is the clearest example. It opens the copay card gate and closes the manufacturer self-pay gate at the same time. Federal coverage closes both. Sorting by who you are rather than by advertised savings gets to the answer in one pass.
The gates, and who each one is built for
| Route | Built for | The gate that rules people out | What it does not do |
|---|---|---|---|
| Manufacturer copay savings card | Commercially insured patients whose plan covers the drug | Federal program beneficiaries are excluded by law | Help anyone whose plan excludes the category |
| Manufacturer direct self-pay | People paying cash without coverage for the drug | Conditions on eligibility and refill timing | Combine with a plan benefit on the same fill |
| Charitable foundation assistance | Households under an income threshold | Funding cycles open and close, and rounds run out | Guarantee ongoing support past a grant period |
| Discount platform rate | Anyone paying cash at a participating counter | None, but rates vary by chain and location | Count toward a deductible or out-of-pocket maximum |
| Employer or plan-specific program | Members of plans that added a weight management benefit | The employer has to have bought the benefit | Survive a plan year in which the employer drops it |
| Flexible spending or health savings funds | People with a qualifying account and a prescription | Requires an account funded in advance | Lower the price, it changes which dollars are used |
Copay cards advertise the largest number and have the narrowest gate
Manufacturer copay assistance produces the biggest headline reduction of any route, which is why it dominates search results. It also carries the tightest restriction: these programs exclude anyone whose prescriptions are paid for by a federal program, and that exclusion is statutory rather than a company policy. Medicare, Medicaid, TRICARE, and VA beneficiaries do not qualify.
The second restriction catches more people than the first. A copay card reduces a copay, so it needs a copay to exist. If a plan excludes the drug outright, there is no copay for the card to work on, and the card does nothing. Medicare Part D rules on weight management coverage are their own separate track, and CMS documentation is the place to check what a given plan is permitted to cover.
Manufacturer direct channels are a different mechanism entirely
Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare sell to self-paying patients on published terms. These are not assistance programs and not discounts on a copay. They are a separate purchase route with their own conditions, commonly around who qualifies as self-pay and how often a refill may be ordered.
Because the terms are set by the manufacturer and published, they change on the manufacturer’s schedule rather than a plan year. Anyone relying on one of these channels should confirm the current terms directly rather than working from a figure quoted in an article, including this one.
Discount platforms are not insurance and not assistance
GoodRx and SingleCare negotiate a cash rate that a participating pharmacy agrees to honor at the register. There is no eligibility screen, which is their main advantage, and no benefit accumulation, which is their main limitation. Spending through a discount platform generally does not count toward a deductible or an out-of-pocket maximum, and a card price cannot be combined with insurance on the same fill.
Their rates also differ by chain, so the cheapest counter without a card is often not the cheapest counter with one. Checking a single platform across several nearby pharmacies is a different exercise from checking several platforms at one pharmacy.
When every gate closes
A large group fails all of them at once: no commercial coverage to activate a card, too much income for a foundation, and a self-pay figure that is still out of reach. What remains is the open cash market, where supervised telehealth practices handle prescribing through a licensed clinician and quote a flat recurring figure. Ro, Hims and Hers, and Henry Meds operate in that space with different product mixes.
There is no eligibility gate of that kind in a compounded program, which means the diligence moves to the provider behind it, to whether the dispensing pharmacy is named and licensed, and to the fact that compounded tirzepatide is not an FDA-approved product. That last point is not a technicality. It is the difference between the two categories.
The route nobody should take
Cheap-search traffic runs into sellers that skip the gates by skipping the law. The FDA has warned about illegally marketed semaglutide and tirzepatide, counterfeit product in the US supply chain, and material sold as for research use or not for human consumption. Its guidance is to purchase only from state-licensed pharmacies. No savings program is worth reaching through a seller that does not require a prescription.
For anyone landing in the open cash market instead, the legitimate self-pay field is quick to survey because the prices sit in the open. Henry Meds, Ro, and Hims and Hers each show their figures, and a Zepbound cost page from HealthRX lays out what the monthly charge is meant to include. Reading two or three of these next to each other finds a workable number faster than applying to programs whose gates have already ruled someone out.
Frequently asked questions
Why are Medicare beneficiaries excluded from copay cards?
Federal rules prohibit manufacturers from offering copay support to patients whose drugs are paid for by federal health programs. It applies across manufacturers and drug classes rather than being specific to this medication, and it cannot be waived by the patient or the pharmacy.
Can a foundation grant be relied on year after year?
Not reliably. Foundation funds are raised and allocated in rounds, and a disease or drug fund can close when a round is exhausted. A grant covering part of a year is common, and planning should assume the possibility that a renewal application arrives at a moment when the fund is closed.
Does a discount platform price count toward a deductible?
Generally no. Using a platform rate means the claim is not processed through the plan, so the spending usually does not accumulate toward a deductible or an out-of-pocket maximum. That can still be the right choice early in a plan year, but it is a trade rather than a free win.
Can two savings routes be stacked on one fill?
Almost never. A pharmacy processes a fill through one payment path, so a plan benefit, a copay card applied to that benefit, or a cash rate applies, but not several at once. The exception is that account funds such as an FSA can pay whatever amount remains due.
What should be checked before assuming a plan excludes the drug?
The formulary document for the specific plan year, not a general statement about the category. Coverage decisions turn on the approved indication being treated, and the tirzepatide label now includes an indication beyond weight management, which some plans handle under different rules.
